Valuation: Novartis AG

Market Cap 284B 248B 229B 211B 398B 27,326B 406B 2,735B 1,076B 13,383B 1,066B 1,042B 46,070B P/E 2026 *
21.7x
P/E 2027 * 18.3x
Enterprise Value 316B 276B 255B 235B 442B 30,407B 452B 3,043B 1,197B 14,892B 1,186B 1,160B 51,266B EV / Sales 2026 *
5.55x
EV / Sales 2027 * 5.18x
Free-Float
91.66%
Yield 2026 *
2.84%
Yield 2027 * 2.93%
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Chief Tech/Sci/R&D Officer 64 16/05/2022
Director TitleAgeSince
Director/Board Member 67 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-0.77% - - 284B
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
-0.36%+3.64%+2.37%-30.88% 143B
Average -0.24%+0.88%+24.86%+45.96% 381.56B
Weighted average by Cap. +0.24%+0.13%+36.22%+78.25%

Financials

2026 *2027 *
Net sales 56.91B 49.73B 45.89B 42.3B 79.72B 5,480B 81.49B 548B 216B 2,684B 214B 209B 9,239B 60.31B 52.71B 48.64B 44.83B 84.5B 5,808B 86.37B 581B 229B 2,845B 227B 222B 9,792B
Net income 14.08B 12.3B 11.35B 10.47B 19.72B 1,356B 20.16B 136B 53.37B 664B 52.87B 51.71B 2,286B 15.64B 13.67B 12.61B 11.63B 21.92B 1,506B 22.4B 151B 59.3B 738B 58.75B 57.46B 2,540B
Net Debt 32B 27.96B 25.8B 23.78B 44.83B 3,081B 45.82B 308B 121B 1,509B 120B 118B 5,195B 28.48B 24.89B 22.97B 21.17B 39.9B 2,743B 40.79B 275B 108B 1,343B 107B 105B 4,624B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
155.01USD
Average target price
152.72USD
Spread / Average Target
-1.48%

Quarterly revenue - Rate of surprise